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Background: To improve the effectiveness of chemo- and radiotherapy only in cancer tissue is important for avoiding side
effects.
Results: Emi1 depletion enhanced the sensitivity of anticancer reagents and X-ray irradiation in cancer cells.
Conclusion: Emi1 siRNA would be a useful new modality for enhancing the effect of chemo- and radiotherapy in various
tumors.
Significance: This work provides new insights regarding synergistic effect of Emi1 knockdown in combination therapies.
Chemotherapy and radiation in addition to surgery has
proven useful in a number of different cancer types, but the
effectiveness in normal tissue cannot be avoided in these thera-
pies. To improve the effectiveness of these therapies selectively
in cancer tissue is important for avoiding side effects. Early
mitotic inhibitor 1 (Emi1) is known to have the function to
inhibit anaphase-promoting complex/cyclosome ubiquitin
ligase complex, which ubiquitylates the cell cycle-related pro-
teins. It recently has been shown that Emi1 knockdownprevents
transition from S to G2 phase by down-regulating geminin via
anaphase-promoting complex/cyclosome activation. At pres-
ent, anticancer drugs for targeting DNA synthesis to interfere
with rapidly dividing cells commonly are used. As Emi1 deple-
tion interfereswith completionofDNAsynthesis in cancer cells,
we thought that Emi1 knockdownmight enhance the sensitivity
for anticancer agents. Here, we confirmed that Emi1 siRNA
induced polyploidy for preventing transition from S toG2 phase
in several cancer cell lines. Then, we treated Emi1 depleted cells
with doxorubicin. Interestingly, increased apoptotic cells were
observed after doxorubicin treatment in Emi1 siRNA-treated
cancer cells. In addition, Emi1 depletion enhanced the sensitiv-
ity of x-ray irradiation in cancer cells. Importantly, synergistic
effect of Emi1 knockdown in these combination therapies was
not observed in normal cells. These results suggest that Emi1
siRNA can be a useful tool for enhancing of sensitivity of cancer
cells to anticancer reagents and radiation.
Approximately 12.7 million cancers were diagnosed and 7.6
million people died of cancerworldwide in 2008 (1). Thismakes
cancer the leading cause of death in the developed world and
the second leading cause of death in the developing world (1).
Cancer can be treated by various means such as surgery, chem-
otherapy, radiation therapy, immunotherapy, and monoclonal
antibody therapy. The choice of therapy depends upon the
location and grade of the tumor and the stage of the disease, as
well as the physical condition of the patient. Complete inacti-
vation of the cancer without damage to the rest of the body is
the goal of treatment. Sometimes this can be accomplished by
surgery, but the propensity of cancers to invade adjacent tissues
or to spread to distant sites by microscopic metastasis often
limits its effectiveness. Chemotherapy alone or in combination
with other treatments such as surgery or radiation has proven
useful in a number of different cancer types, but the effective-
ness of chemotherapy is often limited by the toxicity to non-
targeted tissues in the body. The majority of chemotherapeutic
drugs can be divided into alkylating agents, antimetabolites,
anthracyclines, plant alkaloids, topoisomerase inhibitors, and
other anticancer agents (2, 3). All of these drugs affect cell divi-
sion or DNA synthesis and act by killing cells that divide rap-
idly, one of themain properties ofmost cancer cells. Anticancer
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agents also harm cells that divide rapidly under normal circum-
stances: cells in the bone marrow, digestive tracts, and hair fol-
licles. These effects result in the common side effects of chem-
otherapy, includingmyelosuppression,mucositis, and alopecia.
Therefore, newer anticancer drugs, includingmonoclonal anti-
bodies and the new tyrosine kinase inhibitors, e.g. imatinib
mesylate (Gleevec orGlivec), which directly targets amolecular
abnormality in certain types of cancer (chronic myelogenous
leukemia, gastrointestinal stromal tumors), have been used (4).
Targeted therapy is a type of medication that blocks the growth
of cancer cells by interfering with specific targeted molecules
needed for carcinogenesis and tumor growth, rather than by
simply interfering with rapidly dividing cells. Targeted cancer
therapies thus are expected to be more effective than conven-
tional treatments and less harmful to normal cells.Many oncol-
ogists believe that targeted therapies are the chemotherapy of
the future. At present, however, many traditional anticancer
drugs for targeting DNA synthesis to interfere with rapidly
dividing cells are commonly used. Radiation therapy is the
medical application of ionizing radiation to suppressing tumor
growth. Ionizing radiation works by damaging DNA to control
tumor cell growth/division, but the effect of radiation in normal
tissues cannot be avoided in these therapies.
The cell cycle is regulated by cell cycle regulation factors and
many of these are degraded via ubiquitylation (5). Abnormality
of ubiquitylation in degradation of proteins induces various dis-
eases such as cancer (6–8). It is known that SCF (Skp1-Cullin-
F-box) and anaphase-promoting complex/cyclosome (APC/
C),4 ubiquitin ligases, are involved in ubiquitylation of cell cycle
regulating factors (9, 10). In particular, APC/C is associated
with the degradation of proteins in the M-G1 phase and plays a
role in the regulation of spindle checkpoint and procession
from the M to G1 phase. APC/C is composed of several dozen
subunits, and its activity is regulated by co-activators Cdc20 or
Cdh1 and phosphorylation of constitutive subunits (9). Activity
of APC/CCdc20 increases from the prophase to prometaphase,
and decrease in the anaphase by Cdc20 degradation (9). How-
ever, activity of APC/CCdh1 is maintained from the anaphase to
G1/S phase, after which the activity is inhibited by Emi1 (11).
Emi1 was identified as a factor inhibiting the function of APC/
CCdh1 and is degraded by SCFTrcp at early M phase (12–15). It
recently has been reported that an abnormally high expression
of Emi1 protein can be observed in various cancers (14, 16, 17).
Moreover, inhibition of Emi1 interferes with progression to M
phase by degradation of geminin, which is necessary for the
completion of DNA synthesis (18, 19). Emi1-depleted cells
show polyploidy and large nuclei because these cells cannot
complete DNA synthesis (18, 19). These results suggest that
Emi1-depleted cells remain in S phase. As Emi1 depletion inter-
feres with completion of DNA synthesis in cancer cells (18, 19),
we speculated that inhibition of Emi1 in cancer cells might
enhance the sensitivity of anticancer agents. Moreover, cells
lacking Emi1 undergo DNA damage, likely explained by repli-
cation stress (20). Therefore, we examined the combined effect
of Emi1 knockdown and x-rays. In this study, we also examined
the combined effects by one of the major anticancer agents,
doxorubicin, and Emi1 depletion in various tumor cells.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—Doxorubicin hydrochloride,
camptothecin, etoposide, taxol (paclitaxel), and cobalt chloride
(CoCl2) were obtained from Sigma. Commercial antibodies
were from the following companies: anti-Emi1 and anti-Cul1
antibodies (Zymed Laboratories Inc.); anti-Aurora-A antibody
and anti-fypoxia-inducible factor-1 (HIF-1) (Transduction
Laboratories); anti-cyclin A and anti-cyclin B antibodies (Santa
Cruz Biotechnology); anti-Cdh1 and anti-Cdc20 antibodies,
MBL; anti-E2F1 antibody (Cell Signaling Technology); and
anti--actin antibody (Sigma). Anti-geminin polyclonal anti-
body was gift from Dr. Nishitani (University of Hyogo), and
anti-TPX2 monoclonal antibody was a gift from Dr. Hans-Jür-
gen Heidebrecht (University of Kiel). For detection of the
immunocomplex, the ECL Western blotting detection system
(Amersham Biosciences) was used.
Tissue Samples—Sixty tissue samples of human head and
neck squamous cell carcinomawere retrieved from the Surgical
Pathology Registry of Hiroshima University Hospital, after
approval by the Ethical Committee of Hiroshima University
Hospital. Sixty head and neck squamous cell carcinoma cases
were surgically resected before radiochemotherapy. Clinical
information was gathered from surgical records of the patients.
The histological grade of tumor was classified according to the
criteria of the Japan Society for Head andNeck Cancer. Tissues
were fixed in 10% buffered formalin and embedded in paraffin.
Cell Lines andCultureConditions—Six head and neck cancer
cell lines (HSC2, HSC3, HSC4, Ca9–22, Ho-1-N-1, and Ho-1-
U-1), glioma cell line (T98G), and normal human lung fibro-
blasts (HFLIII) were provided by the Japanese Collection
of Research Bioresources Cell Bank. HOC119, HOC313,
HOC621, HOC719-PE, HOC719-NE, TSU, OM-1, and ZA
cells have been described previously (21). Breast cancer cell line
(MCF-7), colon cancer cell line (RKO and HCT116), osteosar-
coma cell line (SaOS-2), and human breast epithelial cell line
(MCF-10A) were purchased from ATCC. HaCaT cell line was
obtained from N. E. Fusenig (German Cancer Research Cen-
ter). The p53-null HCT116 cell line was obtained from B.
Vogelstein (The Johns Hopkins University). Cells were main-
tained in RPMI 1640 medium or Dulbecco’s modified Eagle’s
medium (Nissui Pharmaceutical Co., Tokyo, Japan) supple-
mented with 10% heat-inactivated FBS (Invitrogen) and 100
units/ml penicillin-streptomycin (Invitrogen) under conditions
of 5% CO2 in air at 37 °C. Upon receiving the cell lines, they
were immediately cultured and expanded to prepare frozen
ampule stocks. Cells were passaged for no more than 2 to 3
months before establishing new culture from early-passage fro-
zen ampules.
RT-PCR—Using the RNeasy mini kit (Qiagen, Hilden, Ger-
many), total RNA from cultures of confluent cells and tissues
was isolated. These isolateswere quantified and their puritywas
evaluated by spectrophotometer. The cDNA was synthesized
from 1 g of total RNA according to ReverTra Dash (Toyobo
Biochemicals, Tokyo, Japan). We used the following primers:
4 The abbreviations used are: APC/C, anaphase-promoting complex/cyclo-
some; DSB, double-stranded break; PI, propidium iodide; EdU, 5-ethynyl-
2-deoxyuridine; NHDF, neonatal normal human dermal fibroblast.
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human Emi1, 5-tctttcgaaggggactcaga-3 (forward) and 5-tct-
ggttgaagcatgaggtg-3 (reverse); human GAPDH, 5-tccac-
caccctgttgctgta-3 (forward) and 5-accacagtccatgccatcac-3
(reverse). Aliquots of total cDNAwere amplifiedwith 1.25 units
of rTaq-DNA polymerase (Qiagen), and this amplification was
done in a thermal cycler (MyCyler, Bio-Rad) for 30 cycles after
initial 30 s of denaturation at 94 °C, annealing for 30 s at 60 °C,
and extension for 1min at 72 °C in all primers used. The ampli-
fication reaction products were resolved on 1.2% agarose/TAE
gels (Nacalai Tesque), electrophoresed at 100 mV, and then
finally visualized by using ethidium bromide.
Immunohistochemistry—Tumor tissues were fixed in 10%
formalin, embedded in paraffin, and cut 4m thick. For immu-
nohistochemical staining, tissue sections were deparaffinized
in xylene and rehydrated in descending grades of ethanol.
Endogenous peroxidase activity was blocked with methanol
containing 0.3%H2O2 for 30min.Antigen retrieval was done by
the microwaving using a citrate phosphate buffer (pH 6.0), and
then the sections were incubated with the primary antibody at
4 °C overnight. Immunohistochemical staining was carried out
by a polyclonal anti-Emi1 antibody (Zymed Laboratories, Inc.).
For detection of the reaction after incubation with secondary
antibodies, we used diaminobenzidine (DAKO, Glostrup, Den-
mark). The sections were counterstained by hematoxylin and
dehydrated in ascending grades of ethanol, and the slides were
mounted. For evaluation of staining intensity, we graded 
(weak/focal immunopositivity),  (strong/focal immunopo-
sitivity and weak/diffuse immunopositivity), (strong/dif-
fuse immunopositivity). Then, the expression of Emi1 was
graded as high (30% of tumor cells showing  or 
intensity) or low (no staining or30%of tumor cells showing
intensity).
Western Blot Analysis—Western blotting was carried out as
described previously (15). The protein concentrations were
measured by Bradford protein assay (Bio-Rad). Twenty g of
protein was subjected to 10% polyacrylamide gel electrophore-
sis, followed by electroblotting onto a nitrocellulose filter. For
detection of the immunocomplex, the ECL Western blotting
detection system (Amersham Biosciences) was used.
Cell Proliferation—For proliferation assay, 5000 cells were
plated onto a 24-well plate, and the cells were allowed to grow
and expand. The cells were then trypsinized and counted at 0, 2,
4, and 6 days by using cell counter (Coulter Z1, Beckman-
Coulter). Doubling time was calculated by rate of cell
proliferation.
Mitotic Index—Cells were seeded on glass coverslips. Forty
eight hours after incubation, cells were fixed, permeabilized,
and stained with pSer-10 histone H3 (Millipore) and DAPI.
pSer-10 histone H3-positive and condensed chromatin cells
were counted as mitotic cells. More than 400 cells were scored
per condition.
RNA Interference—Logarithmically growing cells were
seeded at a density of 105 cells/6-cm dish and transfected with
oligonucleotides at 24 h after replating by usingOligofectamine
(Invitrogen). Forty-eight hours after transfection, lysates were
prepared and analyzed by SDS-PAGE and immunoblotting.
The siRNA is a 19-bp duplex oligoribonucleotide with a sense
strand corresponding to nucleotides 1446–1464 of the human
Emi1mRNA sequence; 5-GAUUGUGAUCUCUUAUUAA-3
(Dharmacon, Chicago, IL). Human cyclin A siRNA (sc-29282)
and human E2F1 siRNA (sc-61861) were obtained from Santa
Cruz Biotechnology. The negative control (siTrio negative con-
trol siRNA) was obtained fromCosmo Bio, Inc. (Tokyo, Japan).
Immunofluorescence—Cells grown on cover slips were fixed
in 4% paraformaldehyde for 10 min at room temperature,
rinsed three timeswith ice-cold PBS, and then permeabilized in
0.1% Triton X-100 in PBS for 15 min at room temperature.
After rinsing three times with PBS, coverslips were incubated
with DAPI staining. Immunostaining of cell preparations was
recorded using an epifluorescence Zeiss Axioplan 2 (Zeiss, Inc.,
Thorwood, NY) microscope attached to a charge-coupled
device camera.
For staining with H2AX, cells were fixed in 4% paraformal-
dehyde for 10 min. Cells were then permeabilized for 2 min in
0.2% Triton X-100 (Sigma) in PBS and washed twice in PBS.
Antibodies were diluted with 4% w/v BSA in PBS. Cells were
incubated withmouse anti-H2AX antibody (Millipore) for 1 h
at 37 °C, washed three times in PBS, and incubated with FITC-
conjugated rabbit anti-mouse IgG antibody (Sigma) for 1 h at
room temperature. Slides were incubated in PBS containing
DAPI for 5 min to stain the DNA and mounted using
Vectashield (Vector Laboratories). Images were captured using
an Olympus DP70 fluorescence microscope. Cell scoring was
carried out blindly with 200 cells/sample ( two individual
experiments).
Flow Cytometry—Cell cycle distribution was determined by
DNA content analysis after propidium iodide (PI) staining
(Sigma). Cells were cultured as described above, fixed in 70%
ethanol, and stored at 4 °C before analysis. Flow cytometric
determination of DNA content was performed on a FACSCali-
bur (Becton-Dickinson, San Jose, CA) flow cytometer. For each
sample, 20,000 events were stored.
For flow cytometric analysis of H2AX, cells were
trypsinized, washed with PBS, and fixed for 10 min in 4% (w/v)
paraformaldehyde and post-fixed in 70% ethanol for at least 2 h
at20 °C. After two washes with PBS, cells were incubated for
10min on ice in hybridization buffer (PBS containing 0.1% BSA
and 0.1%TritonX-100). After centrifugation, cells were hybrid-
ized with mouse anti-H2AX antibody (Millipore) diluted at a
ratio of 1:400 in hybridization buffer and incubated for 2 h in
the dark at room temperature. Cells were washed with hybrid-
ization buffer and incubated with FITC-conjugated rabbit anti-
mouse IgG antibody (Sigma) for 1 h at room temperature. Cells
were then rinsed twice with PBS containing 0.1% Triton X-100
and stained with PI solution (PBS containing 5 g/ml PI, 100
g/ml RNase A) for 30 min before flow cytometry.
5-Ethynyl-2-deoxyuridine (EdU) Labeling—For the labeling
of DNA synthesis, cells were cultured with 10 M EdU for 1 h.
EdU-incorporated cells were detected by using the Click-it
EdU imaging kit (Invitrogen). EdU staining was conducted fol-
lowing the manufacturer’s instructions. Briefly, cells were fixed
with paraformaldehyde for 15min, washed once with PBS, per-
meabilized with 0.2% Triton X-100 buffer for 10 min, washed
once, treated with the click-reaction mixture for 30 min,
washed once, and resuspended in buffer before staining ofDNA
content with PI solution.
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Annexin V and PI Dual-staining Assay—After doxorubicin
treatment, the cells were then stained with phycoerythrin-con-
jugated annexin V and 7-aminoactinomycin D, using the phy-
coerythrin-annexinV apoptosis detection kit (BDPharmingen)
according to the manufacturer’s instructions. Apoptotic cells
were identified by dual-staining with recombinant phycoeryth-
rin-conjugated with annexin V and 7-aminoactinomycin D.
Data acquisition and analysis were done in a FACS Calibur
(Becton-Dickinson) flow cytometer using CellQuest software.
Radiation Exposure and Colony Formation Assay—Sensitiv-
ity to radiation was evaluated by colony formation assays. Cells
were irradiated with x-rays (1.2 gray/min) generated by a
TITAN x-ray irradiator (Shimadzu, Japan) at room tempera-
ture. After irradiation, cells were trypsinized and plated onto
100-mm culture dishes at appropriate cell density. After incu-
bated for 10–14 days, cells were rinsed with PBS, fixed with
100% ethanol, and stained by crystal violet. Colonies consisting
of50 cells were scored as survivor.
Statistical Analysis—Statistical analyses were performed
using STATVIEW (Abacus Concepts, Piscataway, NJ), and a
Fidher protected least significant difference multiple-compar-
ison test was used for all of the analyses in this study. Overall
differences between the groups were determined by one-way
analysis of variance, and Fisher protected least significant dif-
ference multiple comparison test was applied when the results
of one-way analysis of variance were significant (p 0.05).
RESULTS
High Expression of Emi1 Is Frequently Observed in Cancer
Tissues—Recent reports show that high expression of Emi1
protein can be observed in various cancers (14, 16, 17).We also
found Emi1 mRNA overexpression in head and neck cancer
cells (Fig. 1A). Moreover, we investigated Emi1 expression in
various tumor tissues by using the Oncomine database. As
compared with normal counterparts, Emi1 expression was sig-
nificantly increased in many types of tumors, such as head and
neck, breast, prostate, cervix, pancreas, and brain tumors (Fig.
1B). Then, we examined the expression of Emi1 protein in head
and neck cancer cases by immunohistochemistry. Emi1 expres-
sion was graded as high (over 30% of tumor cells showing 
or intensity) or low (no staining or less than 30%of tumor
cells showing intensity). Indeed,most caseswith high expres-
sion of Emi1 showed strong and diffuse immunopositivity and
most cases with low expression of Emi1 showed no or weak
immunopositivity. Expression level of Emi1 in cancer cells was
much higher than that in non-neoplastic cells (Fig. 1C). High
Emi1 expressionwas observed in 53.3%of head andneck cancer
cases and was well correlated with histological differentiation
and lymph node metastasis (Table 1). Moreover, we compared
the expression of Emi1 with p53 and APC/C substrates, cyclin
A, Skp2, and Aurora-A in cancer tissues (Fig. 1D and Table 1).
Interestingly, Emi1 expression was well correlated with p53
expression and APC/C substrates (Table 1).
AsEmi1 itself is an E2F target gene, Emi1mRNAoverexpres-
sion might be caused by activated E2F in cancer cells (20).
Indeed, Emi1 expression was well correlated with the E2F1 and
E2F1 target gene, cyclin E in cancer cell lines, and normal cells
(Fig. 1E). However, Emi1 expression was not correlated with
doubling time and mitotic index (Fig. 1E). Accordingly, E2F1
knockdown reduced Emi1 expression in cancer cells (Fig. 1F).
Emi1 Knockdown Induces Polyploidy in Cancer Cells—As
shown in Fig. 1, Emi1 was frequently overexpressed in various
types of cancer. Next, we examined the effect of Emi1 knock-
down by using siRNA in various types of cancer cell lines. Pre-
vious reports showed that Emi1 depletion induced polyploidy
and large nuclei because cells cannot complete DNA synthesis
(18, 19). Similar to previous reports, we confirmed the effect of
Emi1 knockdown on polyploidy and large nuclei in various can-
cer cell lines, including head and neck cancer (Ca9–22, Ho-1-
U-1, HSC2, HSC3, and HSC4), lung cancer (A549), breast can-
cer (MCF-7), colon cancer (HCT116, HCT116 p53/, and
RKO), glioma (T98G), and osteosarcoma (SaOS-2) (Fig. 2).
Larger nuclei and increased number of cells with polyploidy
were observed in all cancer cells after Emi1 siRNA treatment.
Moreover, the efficiency of Emi1 knockdown was independent
of p53 mutation status (Fig. 2). As shown in Fig. 3A, higher
percentage of cells with polyploidywas observed in cancer cells,
in comparison with that in normal cells. Indeed, Emi1
siRNA-treated cancer cells but not normal cells showed posi-
tive EDU (Fig. 3B), indicating that Emi1 depletion induced
polyploidy through rereplication in cancer cells.
It has been shown that cells lacking Emi1 undergo DNA
damage, likely explained by replication stress upon deregulated
cyclin E- and A-associated kinase activities (20). Here, we exam-
ined the nuclear foci containing phosphorylated histone H2AX
(-H2AX), amarker ofDNAdamage foci in Emi1 depleted cancer
cells (A549, HCT116, and HCT116 p53/) and normal cells
(HFLIII and neonatal normal human dermal fibroblast (NHDF)).
Increased-H2AXfoci andDNAcontentwereobserved incancer
cells, but not in normal cells (Fig. 4A). In particular, frequency of
high levels of H2AX foci (more than 10 foci per cell) in cancer
cells was significantly higher than that in normal cells (Fig. 4B).
Most cells did not show annexin V after Emi1 siRNA treatment
(Fig. 4C). As the expression of phosphohistone H3 was not
observed in Emi1 siRNA-treated cells (Fig. 4D), the elevated level
of H2AXwas not caused by arresting atM phase or induction of
apoptosis. These findings show that replication stress caused by
Emi1 knockdownmight lead to DNA damage.
Next, we examined the detailed mechanism of Emi1 knock-
down in Ca9–22 and Ho-1-U-1 cells. Emi1 is known as an
inhibitor of APC/CCdc20 and APC/CCdh1 (12–15) and inhibi-
tion of Emi1 interferes with progression to the M phase by the
APC/CCdh1-dependent proteolysis of geminin protein (18, 19).
Indeed, expression of Emi1 and APC/CCdh1 substrates such as
Aurora-A and gemininwas down-regulated by Emi1 siRNA treat-
ment in both cells (Fig. 5A). Moreover, Emi1 knockdown signifi-
cantly suppressed proliferation (p  0.05) (Fig. 5B). Then, we
examined theco-depletionofEmi1andCdh1orCdc20 inCa9–22
and Ho-1-U-1 cells. Cdh1 depletion corrected Emi1 knockdown-
inducedpolyploidy to a certain extent (Fig. 5C).As expected, Emi1
knockdown induced down-regulation of APC/CCdh1 substrates
such as Cdc20, cyclin A, cyclin B, Aurora-A, geminin, and TPX2
(Fig. 5D). Cdh1 depletion up-regulated these APC/CCdh1 sub-
strates (Fig. 5D). Thus, as shown in previous reports (18, 19), Emi1
depletion induced rereplication because of geminin down-regula-
tion via APCCdh1-dependent proteolysis.
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Emi1 Knockdown Enhances the Induction of Apoptosis by
Doxorubicin in Human Cancer Cells, but Not in Normal Cells—
Many anticancer agents used in cancer therapy are intended to
control DNA synthesis. Our observations made us hypothesize
that Emi1 depletion in cancer cells might enhance the induc-
tion of apoptosis by anticancer agents. We treated doxorubicin
FIGURE 1. Emi1 overexpression in head and neck cancer. A, Emi1mRNA expression was examined in 14 head and neck cancer cell lines, 2 normal cells, and
20 head and neck cancer tissues by RT-PCR. GAPDH was used as a control. B, mRNA level of Emi1 in different human tumors. All data were provided by the
Oncomine database. Data from Refs. 43–50 were reanalyzed to show expression level of Emi1 in normal brain, glioblastoma, oligodendroglioma, anaplastic
oligodendroglioma, astrocytoma, head and neck cancer, breast cancer, pancreatic ductal adenocarcinoma, cervical cancer, transitional cell carcinoma, and
adult male germ cell tumor (43–50). N, normal tissues; T, tumor tissues. C, immunohistochemical expression of Emi1 in head and neck cancer. D, correlation
between Emi1 expression and APC substrates, cyclin A, and Skp2 expression.We examined the expression of Emi1, cyclin A, and Skp2 in head and neck cancer
cases. A representative head and neck cancer case is shown. E, high expression of Emi1 is regulated by E2F1 in cancer cells. Expression of Emi1, E2F1, and cyclin
E was examined by Western blot analysis in cancer cell lines (HSC2, HSC3, HSC4, Ca9–22, Ho-1-N-1, Ho-1-U-1, HeLa, A549, HCT116, HCT116 p53/, T98G,
SaOS-2, MCF-7, and RKO) and normal cells (HFL III and NHDF). -Actin expression was used as a loading control. The graph shows the mitotic index (%) and
doubling time (h) in each cell. F, E2F1 siRNAwas transfected intoHCT116andHSC2 cells. After 48hof E2F1 siRNA treatment, cellswere collected. Emi1 andE2F1
expression was examined by Western blot analysis. -Actin expression was used as a loading control.
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after Emi1 knockdown inHSC3 andCa9–22 cells. Doxorubicin
treatment induced higher number of subG1 cells in Emi1
depleted cells in comparison with control cells (Fig. 6A).
Annexin V-positive cells were observed in 38.5% of control
(doxorubicin treatment alone) HSC3 cells and 69.59% of Emi1-
depleted HSC3 cells (Fig. 6B). Annexin V-positive cells were
observed in 8.18% of control (doxorubicin treatment alone)
Ca9–22 cells and in 56.67%of Emi1-depletedCa9–22 cells (Fig.
6B). We also examined the induction of apoptosis by doxoru-
bicin treatment in various cancer cell lines (RKO, MCF-7,
A549, HCT116, HCT116 p53/, SaOS-2, and T98G) after
Emi1 depletion. In all cancer cells, the rate of apoptosis was
significantly increased by Emi1 knockdown in combination
with doxorubicin treatment (Fig. 6C). In this study, we used a
common anticancer drug, doxorubicin. We first examined the
induction of apoptosis by other anticancer drugs, camptoth-
ecin, etoposide, and Taxol in HSC3 cells after Emi1 depletion
(Fig. 6D). Camptothecin is the prototypic DNA topoisomerase
I inhibitor, and etoposide is the topoisomerase II inhibitor. Syn-
ergistic effect of Emi1 knockdown in combination with camp-
tothecin and etoposide was observed in HSC3 cells (Fig. 6D).
Taxol stabilizes microtubules and, as a result, interferes with
the normal breakdown of microtubules during cell division.
Distinct from other anticancer agents, Taxol does not affect
DNA synthesis. As we expected, synergistic effect of Emi1
knockdown in combination with Taxol was not observed (Fig.
6D).
Recent study showed that the hypoxic condition induced
multidrug resistance (22). To mimic hypoxia conditions, we
used cobalt chloride (CoCl2). CoCl2 treatment up-regulated
HIF-1 in HSC2 cells (Fig. 6E). Under hypoxia conditions, we
treated doxorubicin after Emi1 knockdown. Indeed, decreased
number of annexin V-positive cells was observed in both con-
trol siRNA and Emi1 siRNA-treated cells under hypoxia condi-
tions (Fig. 6E). Interestingly, a higher number of annexin
V-positive cells was significantly observed in Emi1-depleted
cells, in comparison with control cells under hypoxia condi-
tions (Fig. 6, E and F).
To find out the effect of Emi1 depletion in doxorubicin-
treated normal cells, we examined the induction of apoptosis by
doxorubicin treatment in normal fibroblasts (NHDF and HFL
III) and mammary gland epithelial cells (MCF10A) after Emi1
depletion. Large nucleiwere observed inHFL III cells, but not in
NHDF andMCF10A cells (Fig. 2). Increased G2/M cell popula-
tionwas observed inHFL III cells (Fig. 2). In all normal cells, the
effect of Emi1 knockdown on polyploidy was not observed (Fig.
2). As we checked the reduced expression of Emi1 after Emi1
knockdown in these cells byWestern blot analysis, less effect of
Emi1 knockdownonpolyploidy and large nuclei was not caused
by the transfection efficiency of Emi1 siRNA. In normal cells,
rereplication is known to be induced by co-depletion of gemi-
nin and cyclin A (23).Moreover, both Cyclin A and geminin are
required for suppression of over-replication and for genome
stability inDrosophila cells (24). In this study, down-regulation
of cyclin A was not observed in NHDF cells after Emi1 deple-
tion (Fig. 7A). Although previous reports showed that accumu-
lation of cyclin E was induced by Emi1 knockdown through
activation of theAPC/C-independent pathway (18, 19), up-reg-
ulation of cyclin E was not observed in NHDF cells (Fig. 7A).
Then, we depleted both Emi1 and cyclin A in NHDF cells. As
shown in previous reports (23, 24), knockdown of both Emi1
and cyclin A induced polyploidy and large nuclei (Fig. 7B).
Interestingly, the synergistic effect of Emi1 knockdown on the
induction of apoptosis by doxorubicin treatment was not
observed in NHDF and HFL III cells (Fig. 7C).
Emi1 Knockdown Enhances Radiosensitivity in Human Can-
cer Cells, but Not in Normal Cells—As shown in Fig. 4, Emi1
depletion induced DNA damage in cancer cells, but not in nor-
mal cells. Ionizing radiation works by damaging DNA of
exposed tissue, leading to cellular death. Therefore, we exam-
ined whether Emi1 knockdown affects radiosensitivity in can-
cer and normal cells. We treated Emi1 siRNA in cancer cells
(A549, HCT116 wild type, and HCT116 p53/) and normal
cells (NHDF, HFL III, and MCF10A) and then exposed these
cells to x-rays. Emi1 knockdown markedly increased the cellu-
lar sensitivity to ionizing radiation in these tumor cell lines
(A549 and HCT116 p53 wild type) (Fig. 8). In HCT116 p53/
cells, the survival ratio at low dose (2 gray) showed no signifi-
cant change after Emi1 knockdown, whereas a clear radiosen-
sitization effect was observed by Emi1 knockdown at 4–6 gray
(Fig. 8). On the other hand, Emi1 knockdown did not affect
radiosensitivity at all in normal cells (Fig. 8).
DISCUSSION
We found that Emi1 knockdown inhibited cell proliferation
through induction of rereplication and enhanced the sensitivity
of anticancer reagents and x-ray-treated cancer cells, but nor-
mal cells were not sensitizedwith Emi1 depletion. Interestingly,
Emi1 was found to be up-regulated in several human tumors
(11, 16, 17). APC/C inactivation by Emi1 leads to accumulation
of APC/C substrates for progression of S phase and early mito-
sis (11, 14). Lehman et al. (16) found frequent overexpression of
APC/C substrates (securin, Plk1, Aurora-A, and Skp2) and
Emi1 in a large number of malignant tumors by immunohisto-
chemical staining of tissue microarrays. Importantly, several or
all of the APC/C substrates clustered together in various
TABLE 1
Summary of Emi1 expression in head and neck cancer
Total
Emi1 expression
p valueLow High
Head and neck cancer 60 28 (46.7%) 32 (53.3%)
Histological differentiation
Well 11 8 (72.7%) 3 (27.3%) 0.02
Moderate 37 18 (48.6%) 19 (51.4%) 0.02
Poor 12 2 (16.7%) 10 (83.3%) 0.02
Lymph node metastasis
Negative 40 23 (57.5%) 17 (42.5%) 0.02
Positive 20 5 (25.0%) 15 (75.0%) 0.02
Cyclin A expression
Low 27 21 (77.8%) 6 (22.2%) 0.00001
High 33 7 (21.2%) 26 (78.8%) 0.00001
Skp2 expression
Low 25 15 (60.0%) 10 (40.0%) 0.08
High 35 13 (37.1%) 22 (62.9%) 0.08
Aurora-A expression
Low 27 19 (70.3%) 8 (29.7%) 0.0008
High 33 9 (27.3%) 24 (72.7%) 0.0008
p53 expression
Low 19 13 (68.4%) 6 (31.6%) 0.02
High 41 15 (36.6%) 26 (63.4%) 0.02
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tumors with elevated Emi1 protein (16). Moreover, Emi1 over-
expression leads to unscheduled cell proliferation, tetraploidy,
and chromosomal instability in p53-deficient cells (25). Nota-
bly, Emi1 is the target of E2F transcription factors (11), poten-
tially linking the frequent deregulation of the E2F pathway to
APC/Cderegulation. This observation is supported by our find-
ings that (i) Emi1 expression was well correlated with E2F1
expression in cancer cells (Fig. 1E), and (ii) E2F1 knockdown
down-regulated Emi1 expression (Fig. 1F). We also confirmed
that Emi1 is frequently overexpressed in various cancers,
including head and neck cancers, and that Emi1 expression is
well correlated with Aurora-A and Skp2 expression. These
FIGURE 2. Emi1 knockdown in various cancer cell lines. Emi1 siRNAwas transfected into various cancer cell lines, including head and neck cancer (Ca9–22,
Ho-1-U-1, HSC2, HSC3, and HSC4), lung cancer (A549), breast cancer (MCF-7), colon cancer (RKO, HCT116, and HCT116 p53/), glioma (T98G), and osteosar-
coma (SaOS-2). Em1i siRNA was also transfected into normal cells, including NHDF (dermal fibroblast), HFL III (fibroblasts), and MCF10A (mammary gland
epithelial cells). The status of p53was shown in each cell line. Cellswere stainedwithDAPI to visualize thenuclei. Cell cycle distributionwasdeterminedbyDNA
content analysis after PI staining using a flow cytometer. Scale bar, 100 m. IF, immunofluorescence.
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findings suggest that deregulation of Emi1 may contribute to
APC/C inactivation in cancer.Moreover, head and neck cancer
cases with high expression of Emi1 showed malignant behav-
iors, including poor differentiation and lymph nodemetastasis,
suggesting that Emi1 can be a possible therapeutic target in
cancer.
FIGURE 3. Emi1 knockdown induced polyploidy in various cancer cell lines. A, the graph shows the percentage of cells with polyploidy in various cells.
Percentage of cells with polyploidy was analyzed by a flow cytometer as shown in the figure. B, EdU staining was examined in various cells (A549, HCT116,
HCT116 p53/, MCF-7, T98Gm RKO, HFLIII, and NHDF) by a flow cytometer after control siRNA or Emi1 siRNA treatment.
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DNA replication depends on the APC/C-mediated degrada-
tion of geminin, which releases the inhibition of Cdt1 incorpo-
ration into prereplicative complexes and permits the proper
assembly of these complex components (26, 27). Origin firing
can only occur after the APC/C is inactivated and CDKs
become active. To strictly inhibit the assembly of prereplicative
complexes during S to G2 phase transition, APC/C is inacti-
vated by several mechanisms: binding to its inhibitor Emi1,
CDK-mediated phosphorylation of Cdh1 (which blocks its abil-
ity to activate APC/C), and degradation of both Cdh1 (28) and
its major ubiquitin C, namely UbcH10 (29). Indeed, Emi1
depletion induced rereplication with large nuclei and poly-
ploidy in various cancer cells (Fig. 2), and Cdh1 rescued the
down-regulation of geminin and rereplication caused by Emi1
FIGURE4.DNAdamage inEmi1depletedcancer cells.A, Emi1 knockdown induceH2AX foci in tumor cells. Tumor cells (A549,HCT116, andHCT116p53/)
and normal cells (HFLIII and NHDF) were transfected with the indicated siRNA. After 48 h the transfection, cells were fixed and stained with anti-H2AX
antibodies. The levels of H2AX phosphorylation were detected using by the flow cytometer. Bivariate distributions representing expression of H2AX versus
DNA content of tumor and normal cells are shown. The levels of H2AX phosphorylation were also detected using by the fluorescencemicroscope. Represent-
ative images ofH2AX immunostaining (green) andnuclear staining (blue) in tumor or normal cells are shown. B, images on the left show typical images of cells
presenting low (010 foci/cell) or high levels of H2AX foci or showing pan-nuclear staining H2AX. The right graph indicates percentages of cells with high
level (10 foci/cell) of H2AX foci. Results presented are themeans of two independent experiments S.D. C, apoptosis was examined by annexin V staining
using a flow cytometer in various cells (A549, HCT116, HCT116 p53/, HFLIII, and NHDF) after control siRNA or Emi1 siRNA treatment. D, expression of
phosphohistoneH3 (pHH3)was examinedby the fluorescencemicroscope in A549 andHFLIII cells after control siRNAor Emi1 siRNA treatment. Cells were also
stained with DAPI to visualize the nuclei.
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depletion (Fig. 5C). These findings are consistent with previous
findings showing that (i) rereplication caused by Emi1 deple-
tion is due to decreased geminin via APC/C-mediated proteol-
ysis (18, 19), and (ii) geminin depletion causes rereplication in
cancer cells (30). In addition, Emi1 depletion induces DNA
damage, likely explained by replication stress upon deregulated
cyclin E- and A-associated kinase activities (20). We also found
that Emi1 knockdown induced the frequency of high levels of
H2AX foci (10 foci per cell) in cancer cells (Fig. 4B). H2AX
foci are known to be an early response marker for double-
stranded breaks (DSBs) (31).Moreover, premature termination
of DNA replication can lead to fork collapse and consequent
DSBs, eventually triggering robust activation of the DNA dam-
age checkpoint response (32). Therefore, Emi1 depletion is
likely to induce DSBs via replication stress. Interestingly, fre-
quency of high levels of H2AX foci by Emi1 depletion in can-
cer cells was higher than that in normal cells (Fig. 4B). Chemo-
therapy and/or radiation in addition to surgery have proven
useful in a number of different cancer types. At present many
anticancer drugs for targeting DNA synthesis to interfere with
rapidly dividing cells are commonly used. Ionizing radiation
works by damaging DNA of exposed tissue leading to cellular
death. Therefore, the finding that Emi1 depletion induced
rereplication andDNA damagemade us hypothesize that Emi1
knockdown might enhance the sensitivity of anticancer drugs
and ionizing radiation. Interestingly, in the present study, we
demonstrated that Emi1 knockdown by using siRNA enhanced
the sensitivity of anticancer reagents treatment and x-rays in can-
cer cells.Althoughwe found synergistic effect ofEmi1knockdown
in combination with doxorubicin, camptothecin, and etoposide
(Fig. 6D),we areplanning to examine the synergistic effect of Emi1
knockdown in combination with other anticancer drugs that
interfere with DNA synthesis. Recent study showed that the
hypoxic condition induced multidrug resistance (22). Interest-
ingly, Emi1 siRNA enhanced the sensitivity of anticancer drugs
under hypoxia condition (Fig. 6, E and F), indicating that Emi1
depletion can be a useful for clinical application.
It is likely that the radioresistance is strong in the S phase
because the DNA repair enzymes that allow radiation-induced
damage to appear in DNA are at full activity during S phase and
less so at other stages (33). The G2/M phase of the cell cycle is
when cells are most sensitive to radiation (33). Indeed, pacli-
FIGURE 5. DNA damage and polyploidy by Emi1 knockdown via activation of APC/CCdh1. A, Emi1 siRNA was transfected into HSC3 or Ca9–22 cells. After
48 h of Emi1 siRNA transfection, cellswere collected. The indicated proteinswere examinedbyWestern blotting. B, Emi1 siRNA inhibits cell growth in head and
neck cancer cells. Cell growth of Ho-1-U-1 cells after Emi1 siRNA transfection. After 48 h of transfection, cells were plated in 24-well plates. Cells were counted
byCell Counter at 0, 2, 4, and6days.Weassayed three times.C, Emi1 siRNA inducespolyploidy throughactivationofAPC/C.Co-depletionofCdh1orCdc20with
Emi1 by siRNA in Ca9–22 and Ho-1-U-1 cells. These cells were transfected with the indicated siRNAs. Cell cycle distribution was determined by DNA content
analysis after PI staining using a flow cytometer. D, co-depletion of Cdh1 or Cdc20 with Emi1 by siRNA in Ca9–22 and Ho-1-U-1 cells. The indicated proteins
including APC/CCdh1 substrates in siRNA-treated cells were examined by Western blotting.
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taxel, which inhibits the formation of mitotic spindles and
arrests the cells in G2/M phase, enhances radiation efficacy on
cell killing and suppression of growth (34–36). Moreover, inhi-
bition of Aurora kinase enhances the sensitivity of radiation
(37–40). Thus, some drugs for inducing cell cycle arrest at M
phase are used for enhancing the sensitivity of radiation.
Although Emi1-depleted cells were arrested at S phase by
rereplication decreased survival cells was observed after x-ray
exposure. As Emi1 depletion leads to DSBs via replication
stress, DSBs induced by Emi1 depletion may enhance the sen-
sitivity of radiation in cancer cells.
Emi1 knockdown suppressed cancer cell growthwith contin-
uous DNA synthesis, but normal cells did not seem to be
affected by the knockdown. Therefore, the synergistic effect of
FIGURE6.Synergistic anticancer effectof Emi1knockdown in combinationwithdoxorubucin in cancer cells.A, after 48hof Emi1 siRNA transfection, cells
were treated with doxorubicin (0.5 g/ml) for 12 h. Cells were fixed in 70% ethanol. Cell cycle distribution was determined by DNA content analysis after PI
stainingusing a flow cytometer. For each sample, 20,000 eventswere stored. Percentageof the sub-G1 population is indicated. Representative data are shown.
Weperformed three independent experiments. B, flow cytometric analysis of annexin V andPI staining in control and Emi1 siRNA-treatedHSC3or Ca9–22 cells
after treatment with doxorubicin (0.5 g/ml) for 12 h. We performed three independent experiments. C, synergistic anticancer effect of Emi1 knockdown in
combination with doxorubucin (DOXY) in various cancer cells. Graph shows the average percentage of apoptotic cells in various cancer cells after treatment
withdoxorubicin (0.5g/ml) for 12h. In this study, various cancer cell lines including lungcancer (A549), breast cancer (MCF-7), coloncancer (RKO,HCT116, and
HCT116 p53/), glioma (T98G), and osteosarcoma (SaOS-2) were used. We performed three independent experiments. *, p 0.05. D, synergistic anticancer
effect of Emi1 knockdown in combination with camptothecin and etoposide but not with Taxol in HSC3 cells. The graph shows the average percentage of
apoptotic cells in HSC3 cells after treatment with camtothecin (2 M), etoposide (1 M), or Taxol (1 nM) for 12–24 h. We performed two independent
experiments. *, p  0.05. E, hypoxic condition induced drug resistance. CoCl2 (100 M) was treated for 6 h in HSC2 cells after 24 h of control or Emi1 siRNA
transfection. Cells were collected and expression of HIF-1 and Emi1was examinedbyWestern blot analysis.-Actin expressionwas used as a loading control.
After 6 h of CoCl2 treatment, doxorubicin (DOXY; 0.5 g/ml) was treated for 12 h in control or Emi1-depleted cells. Graph shows the average percentage of
apoptotic cells (annexin V-positive cells) in HSC2 cells after treatment with doxorubicin for 12 h under normal or hypoxia condition (CoCl2 treatment). We
performed two independent experiments. *, p 0.05. F, synergistic anticancer effect of Emi1 knockdown in combination with doxorubicin in HSC3 and HSC4
cells under hypoxia conditions. The graph shows the average percentage of apoptotic cells (annexin V-positive cells) in HSC3 and HSC4 cells after treatment
with doxorubicin for 12 h under normal or hypoxia conditions (CoCl2 treatment). We performed two independent experiments. *, p 0.05.
FIGURE 7. Synergistic anticancer effect of Emi1 knockdown in combination with doxorubucin in normal cells. A, Emi1 or control siRNA was transfected
into NHDF cells, and cells were collected after 48 h. The indicated proteins in siRNA-treated NHDF cells were examined by Western blotting. B, Emi1 siRNA
and/or cyclin A siRNAwere transfected into NHDF cells. The left panel shows the expression of Emi1 and cyclin A examined byWestern blot analysis after 48 h
of siRNA transfection.-Actin expressionwas used as a loading control. The right panel showsDAPI staining and percentage of cells with polyploidy after Emi1
siRNA and/or cyclin A siRNA transfection. Cells were stainedwith DAPI to visualize the nuclei, and percentage of cells with polyploidy was determined by DNA
content analysis after PI staining using a flow cytometer. *, p 0.05. C, flow cytometric analysis of annexin V and PI staining in control and Emi1 siRNA treated
NHDF or HFL III cells after treatment with doxorubucin (DOXY; 0.5 g/ml) for 12 h. We performed three independent experiments.
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Emi1 knockdown in combination with doxorubicin treatment
and radiation was not observed in normal cells. These findings
are consistent with previous finding that none of the effects are
detected either in normal cells by geminin depletion (23). In
normal cells, both geminin and cyclin A suppress rereplication
and genomic instability (23, 24). In this study, down-regulation
of cyclin A was not observed in normal fibroblasts after Emi1
depletion (Fig. 7A), whereas down-regulation of cyclin A was
observed in cancer cells (Fig. 5D). As shown in Fig. 1, overex-
pression of Emi1 andAPC/C substrates, including cyclinA, was
observed in cancer cells. Activated APC/C by Emi1 depletion
may degrade overexpressed APC/C substrates at S-G2 phase in
cancer cells but not in normal cells. In normal cells, inhibitory
mechanism of degradation of APC/C substrates may exist at
S-G2 in addition to proper phase for their protein degradation.
Indeed, depletion of both Emi1 and cyclinA induced polyploidy
and large nuclei (Fig. 7B). Therefore, cyclin A may suppress
rereplication innormal cells.Thisobservation is supportedbypre-
vious finding that treatment with geminin siRNA and cyclin A
siRNA induced DNA rereplication in normal cells in similar to
cancer cells induced by geminin siRNA alone (23). Previous
reports showedthataccumulationofcyclinEwas inducedbyEmi1
knockdown through the APC/C-independent pathway (18, 19).
As cyclin E is not a substrate ofAPC/C, it is still unclearwhy cyclin
E is up-regulated by Emi1 depletion. Interestingly, up-regulation
of cyclin E was not observed in normal cells (Fig. 7A), suggesting
that induction of cyclin Emay be involved in rereplication only in
cancer cells. These findings suggest that Emi1may play an impor-
tant role in initiatingDNAreplication incancer cells,whereasnor-
mal cells may possess additional safeguards such as cyclin A for
preventing DNA rereplication. Importantly, no effect of Emi1
knockdown and no synergistic effect of Emi1 knockdown in com-
binationwith doxorubicin treatment and radiation in normal cells
are useful findings for clinical application.
The therapeutic utility of siRNAs is thought to be limited by
the requirement for complex formulations to deliver them to
tissues. Recently, however, it has been identified single-strand
siRNAs for silencing gene expression in animals (41). Indeed,
single-strand siRNAs achieved potencies and selectivity for
inhibiting mutant huntingtin in Huntington disease model
mice (42). It is anticipated that technologies of siRNA delivery
will be developed for efficient gene silencing in clinical applica-
tion.Moreover, we will look for the small compound or peptide
for inhibiting Emi1 function in addition to siRNA. In conclu-
sion, we suggest that inhibition of Emi1 function could be a
useful for enhancing sensitivity of cancer cells to chemothera-
peutic drugs and ionizing radiation.
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FIGURE8.Synergistic anticancereffectofEmi1knockdown incombinationwith radiation.Theeffectsof Emi1knockdownoncell survival ofA549,HCT116
wild type, andHCT116p53/, HFLIII, NHDF, andMCF10Acells. Cellswere transfectedwith Emi1 siRNAornegative control siRNA.After 48h, cellswere exposed
to 0–6 gray x-rays. Cell survival was determined by a colony formation assay. Data shown are mean and S.E. of three independent experiments.
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